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intrOdUctiOn
“Regenerative medicine” refers to therapies that aim to restore normal form and function using the 
body’s own biological machinery, such as stem cells and biologics. The use of regenerative medicine 
to treat injury and disease offers new hope to cure previously frustrating diseases and conditions. 
However, commercialization of biologic therapies in veterinary medicine has outpaced the speed of 
clinical research, and we are at risk of harming the reputation and standing of regenerative medicine 
before it has been fully optimized and developed. In response to this, international regulation of 
Veterinary Regenerative Medicine is underway. This highlights the need and opportunity for vet-
erinarians and veterinary researchers to influence the optimal development of this field by working 
toward standardized approaches and evidence-based medicine.
The Frontiers journal approach to publication allows a more collaborative environment and 
enables a more sophisticated discussion about emerging challenges that need to be addressed in 
our work. My vision for the Veterinary Regenerative Medicine specialty section of Frontiers in 
Veterinary Science is to facilitate the timely publication of high-quality research articles in Veterinary 
Regenerative Medicine and to host discussion about provocative topics in our field. As the first 
journal with a section focused on Veterinary Regenerative Medicine, Frontiers in Veterinary Science 
has the opportunity of providing a much-needed forum for these timely topics.
Emerging challenges that are relevant to the development of safe and efficacious regenerative 
therapies for veterinary patients include the proper validation of reagents used in veterinary 
research, standardization of protocols and nomenclature, and highlighting the limitations as well 
as clinical relevance of research findings. Furthermore, another challenge to the field is merging 
complex processes and unique techniques associated with cell culture with a medical field that has 
established treatments and surgeries that may be used alongside regenerative therapies. This makes 
optimizing therapeutic approaches more complex, costly, and time consuming in the veterinary 
medical field where achieving evidence-based medicine is already challenging. Finally, advances in 
Veterinary Regenerative Medicine should be relevant and available to those studying human disease 
and basic science if it is to have its most profound impact. The open access format for Veterinary 
Regenerative Medicine offers a venue for dissemination of information about veterinary therapeutics 
that can accelerate translational medicine and the concept of “One Health.”
reGUlatiOn OF Veterinary reGeneratiVe Medicine
In the European Union, the United States, Japan, and other countries, the regulatory framework for 
the therapeutic use of stem cells for human patients is well established (1). In contrast, the veterinary 
medical field has taken longer to develop these frameworks. In the United States, the Center for 
Veterinary Medicine (CVM) within the U.S. Department of Health and Human Services’ Food 
and Drug Administration (FDA) has initiated steps to regulate the field of Veterinary Regenerative 
Medicine in parallel with the regulatory environment of human regenerative medicine therapies.
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In June 2015, the FDA published guidelines on the regulation 
of veterinary cell therapy (2). While a comprehensive survey of 
the international regulation of Veterinary Regenerative Medicine 
is outside the scope of this article, key features to glean from 
this FDA document include understanding whether cell therapy 
for veterinary patients is treated similarly or differently from 
human patients, what type of cell therapy constitutes a drug, and, 
if it is a drug, what level of manufacturing practice is required. 
Specifically for the US, this guidance document broadly consti-
tutes what cell therapies require FDA approval, namely, allogeneic 
and xenogeneic cell therapies, and autologous therapies that are 
more-than-minimally manipulated, or that are used in a non-
homologous manner, or that are used in food-producing animals, 
or that are combined with other drugs or devices for therapy. Any 
cell therapy that falls under these broad characteristics requires 
opening an Investigational New Animal Drug (INAD) file for 
any client-owned animal research that is to be undertaken and 
commercial products require New Animal Drug Application 
(NADA) approval. CVM used many of the guidelines developed 
for human cellular therapy by the FDA Center for Biologics 
Evaluation and Research (CBER). Thus, definitions of terms, such 
as “autologous,” “minimally manipulated,” “homologous usage,” 
and “good manufacturing processes” could be applied similarly 
for both humans and animals. It is notable that since the FDA 
evaluates each product and its data independently, the guidance 
document cannot be used a priori to know whether a therapy will 
require FDA approval for clinical use.
Internationally, regulatory bodies may take a different approach 
and not apply similar standards from human to veterinary cell 
therapies. Frontiers in Veterinary Science welcomes review arti-
cles about the regulation of Veterinary Regenerative Medicine 
since this is such a critical and timely topic to practitioners and 
researchers alike. For those of us with interests in academic 
research regardless of nationality, validation of protocols and 
procedures is a critical step toward regulatory approval and effec-
tive and safe application of regenerative therapeutics. To bring 
Veterinary Regenerative Medicine to its full clinical potential, 
funding for studies both validating the laboratory-based aspects 
of regenerative medicine and the clinical safety and efficacy of 
treatments is critical.
ValidatiOn OF reaGentS USed in 
Veterinary reSearch
The ability to conduct sophisticated cell and molecular biological 
research in veterinary species has entered a heyday. Since the 
sequencing of the human genome, the reduced cost and increased 
availability of sequencing facilities have enabled sequencing of 
many other species’ genomes, including the horse, dog, cat, and 
cattle (3–6). This, together with the ease of quantitative PCR tech-
niques, has given veterinary researchers access to study a host of 
gene expression patterns in response to experimental manipula-
tion. The caveat is that as veterinary clinical researchers, we need 
a deep understanding of the molecular biology behind the assays 
and an incomplete understanding of the pitfalls of the assays and 
requirements for validation can limit the quality of our research. 
One example is that relative gene expression reliability and valid-
ity rely upon the use of a stably expressed gene or panel of genes 
in whatever system is being studied (7). Few publications in our 
field validate or address the stability of reference genes prior to 
calculating relative gene expression (8, 9). The proper design and 
validation of quantitative PCR assays is another area in need of 
further work. In particular, the use of SYBR green qPCR over 
TaqMan without adequate optimization of the SYBR green assay 
can result in unreliable data (10, 11). The MGB probe within the 
TaqMan assays reduces the chance of spurious results; however, 
this assay is not dominant in the veterinary literature to date.
Antibody-based assays are exceptionally important in cell 
and molecular biology research, and this is one area of weakness 
for veterinary research, since antibody reagents have not been 
readily available for our species of interest. That being said, the 
number of reagents that have been tested for cross-reactivity in 
veterinary species has increased, and biotechnology companies 
are beginning to see more value in creating equine or canine-
specific antibodies due to increased demand. The proper valida-
tion of antibodies for an assay is a time consuming and expensive 
procedure but it is integral to the validity of our research (12). 
Ideally, an antibody that immunoprecipitates the protein can be 
validated by mass spectroscopy. Another approach to validation 
is to identify that only one protein is recognized by an antibody 
via Western blot analysis, and that expression levels (either on 
Western blot, immunofluorescence, or flow cytometry) correlate 
to any knock-down, knock-out, or down- or upregulation experi-
ments. Without access to genomic knock-outs and with limited 
availability of predesigned commercially available knock-down 
reagents, such as siRNA for veterinary species, this process is 
more difficult and costly. Moreover, it is important to note that 
Western blots recognize denatured or non-denatured but non-
native protein configurations. Secondary, tertiary, and quater-
nary native structure of a protein might be critical for epitope 
recognition, and native structure is often important for epitope 
recognition and effective antibody reagents for flow cytometry 
and immunofluorescence.
These difficulties do not obviate the need for validation; they 
highlight that a cooperative and collaborative approach to reagent 
validation would be beneficial to the entire field. Some published 
experiments using antibody-based assays have not been repro-
ducible; the Veterinary Regenerative Medicine specialty section 
can provide a forum for optimization and validation of antibody 
reagents. We are including a “Protocol” publication type to aid in 
the dissemination of the detailed information needed for veteri-
nary researchers to successfully move our field forward.
StandardiZatiOn OF prOtOcOlS and 
nOMenclatUre
In the human and rodent model literature, much effort has been 
made to standardize the nomenclature of stem cells, including 
mesenchymal stromal cells, hematopoietic stem cells, and embry-
onic stem cells (13, 14). In contrast, much of the veterinary litera-
ture lacks detailed characterization of stem cell lines presumably 
partly due to limited resources available to veterinary researchers, 
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and partly due to lack of reagents available for veterinary species. 
To avoid researchers repeating protocols or approaches that are 
not dependable, we need to pool our knowledge about inconsist-
ently reliable reagents and results that may not be reproducible 
in a cooperative forum. We are fortunate for the opportunity to 
investigate species differences in stem cell function, gene expres-
sion, and cell surface expression to better elucidate properties that 
contribute to effective regenerative therapies. Beyond the scien-
tific literature, commercially available veterinary therapies use 
terminology that is not consistent with the guidelines present in 
the human literature. For example, referring to stromal vascular 
fraction cells as “stem cells” is not consistent with position state-
ments on the human side. Similarly, platelet-rich plasma is a term 
that has been applied to platelet and leukocyte-rich plasma, and 
platelet-rich but plasma-reduced blood products. There has been 
considerable effort in human therapy to standardize nomencla-
ture of blood-based therapies. For veterinary medicine, this has 
begun, but further clarification and consensus is needed. There 
are serious concerns that inconsistent or inaccurate labeling of 
regenerative medicine products could impact the public’s percep-
tion of the efficacy of stem cell therapies, as well as biologics.
Furthermore, protocols for stem cell isolation, characteriza-
tion, and differentiation vary from laboratory to laboratory, and 
the response of stem cells to those protocols can vary based on 
both the species and the tissue of origin of the stem cells (15, 
16). We invite articles that take a broad look at protocols in the 
literature and relate relative efficacy of differentiation to whether 
the protocols were optimized to the species and tissue of origin. 
As Frontiers in Veterinary Science is an open access journal, 
review articles, editorial commentary, and potentially consor-
tium statements published on this topic could act as a primary 
source of reliable information available to whomever is searching 
for information about stem cell therapy for veterinary patients.
clinical releVance OF reSearch 
FindinGS
Regenerative medicine research aims to use the natural machinery 
in the body to improve the clinical outcomes for various diseases 
and conditions; however, much of the research needed to develop 
these clinical approaches can be difficult to interpret for clini-
cians. Another goal of this specialty section is to provide com-
mentary and review articles highlighting the clinical relevance of 
recent research publications. Moreover, the open review process 
we use at Frontiers allows readers to see the reviewers’ critiques, 
which often highlight where more research is needed before a 
given treatment is accepted as both safe and efficacious for clinical 
use. The education of clinicians about the differences between cell 
therapies or even tissue engineered materials is a critical part of 
what we hope to do in this specialty section. Potential topics we 
could focus on include studies or articles that discuss collection 
of tissues from patients and the use of cell therapies for injection 
of lesions. At Frontiers in Veterinary Science, we also invite articles 
and editorials that accompany primary research articles to relate 
innovative research findings to veterinary clinical practice now 
and in the future.
One health and a challenGe FOr 
Veterinary reSearcherS
Open access journals allow the dispersal of information rapidly 
and broadly. For Frontiers in Veterinary Science, this allows basic 
scientists and researchers studying human disease and basic sci-
ence to access the veterinary literature, which is often unavailable 
at universities that do not have a college of veterinary medicine. 
Publication of high quality Veterinary Regenerative Medicine 
research and communicating the field broadly may fertilize col-
laboration and interaction across human and veterinary medicine 
and science. Also, having all of Veterinary Regenerative Medicine, 
whether it refers to small animals or large animals in the same 
specialty section further promotes the concept of “One Health.” 
The field of regenerative medicine and stem cell biology is grow-
ing exponentially, and this trend has now included Veterinary 
Regenerative Medicine. Taking a broader look at the regenerative 
medicine field and teasing out literature in non-veterinary pub-
lications that relates to veterinary medicine is another potential 
benefit of this specialty section.
cOnclUSiOn
In summary, the Veterinary Regenerative Medicine specialty sec-
tion of Frontiers in Veterinary Science invites high quality primary 
research articles in Veterinary Regenerative Medicine and stem 
cell biology for submission, as well as review articles, editorials, 
cases reports, protocols, and retrospectives. We encourage the 
Associate Editors and Review Editors to support the mission of 
the specialty section by using an open, interactive, constructive, 
and rapid review process to develop and advance articles prior to 
publication. The last challenge I put forth is the development of 
Research Topics, which generate focused collections of articles on 
a specific topic important to Veterinary Regenerative Medicine.
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